Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) Director Kush Parmar sold 1,718 shares of the stock in a transaction on Friday, July 31st. The stock was sold at an average price of $6.85, for a total value of $11,768.30. Following the completion of the sale, the director directly owned 2,846,592 shares in the company, valued at approximately $19,499,155.20. This represents a 0.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Kush Parmar also recently made the following trade(s):
- On Thursday, July 30th, Kush Parmar sold 114,756 shares of Entrada Therapeutics stock. The stock was sold at an average price of $6.93, for a total transaction of $795,259.08.
Entrada Therapeutics Price Performance
TRDA stock traded up $0.47 during trading on Monday, hitting $7.26. 500,498 shares of the stock traded hands, compared to its average volume of 329,656. Entrada Therapeutics, Inc. has a 1 year low of $4.93 and a 1 year high of $16.45. The firm’s 50 day moving average is $6.83 and its two-hundred day moving average is $9.84. The stock has a market cap of $281.84 million, a price-to-earnings ratio of -1.82 and a beta of -0.26.
Analyst Ratings Changes
Several equities analysts recently issued reports on the company. Weiss Ratings cut Entrada Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. Oppenheimer lifted their target price on Entrada Therapeutics from $21.00 to $23.00 and gave the stock an “outperform” rating in a report on Monday, April 6th. Roth Capital set a $10.00 price target on Entrada Therapeutics in a research note on Friday, May 8th. HC Wainwright downgraded Entrada Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Finally, Guggenheim dropped their price objective on Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research report on Monday, June 8th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Entrada Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $17.50.
Get Our Latest Stock Analysis on TRDA
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the stock. Baker BROS. Advisors LP lifted its position in Entrada Therapeutics by 4.3% during the fourth quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock valued at $52,148,000 after purchasing an additional 206,911 shares during the period. Wellington Management Group LLP grew its position in Entrada Therapeutics by 9.5% in the 4th quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock worth $10,740,000 after purchasing an additional 90,339 shares during the period. Millennium Management LLC raised its stake in Entrada Therapeutics by 391.2% during the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after buying an additional 666,287 shares during the last quarter. Geode Capital Management LLC raised its stake in Entrada Therapeutics by 7.2% during the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after buying an additional 42,479 shares during the last quarter. Finally, State Street Corp lifted its holdings in shares of Entrada Therapeutics by 2.0% during the 4th quarter. State Street Corp now owns 508,789 shares of the company’s stock valued at $5,230,000 after buying an additional 10,174 shares during the period. 86.39% of the stock is owned by hedge funds and other institutional investors.
Entrada Therapeutics Company Profile
Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.
The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.
Read More
- Five stocks we like better than Entrada Therapeutics
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
